HRTX Q3 2018 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+130.8% YoY

Gross Profit

$12M61.7% margin

Operating Income

-$42M-211.2% margin

Net Income

-$38M-193.8% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+14.5%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$39M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$471M

Total Liabilities

$64M

Stockholders' Equity

$407M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$9M	+130.8%
Gross Profit	$12M	$8M	+62.3%
Operating Income	-$42M	-$41M	-1.1%
Net Income	-$38M	-$42M	+8.4%